Shares of Dr Reddy's Laboratories (DRL) rose over 3 per cent today as the company received US health regulator's approval to market ZembraceSymTouch injection for treatment of acute migraine, in the American market.
The stock gained 3.21 per cent to settle at Rs 3,103.60 on BSE. Intra-day, it rose 3.58 per cent to Rs 3,115.
At NSE, shares of the company moved up 3.12 per cent to Rs 3,105.40.
The company has received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection, DRL said in a statement today.
ZembraceSymTouch is available as a prefilled, ready to use, single dose disposable injector.
"This is a major milestone for the company as we continue to bring innovative medicines to patients and physicians," DRL CEO and Co-Chairman GV Prasad said.
The new product will be marketed in the US by Promius Pharma, a wholly-owned subsidiary of the company.
